Pierre Fabre gets EC nod for Braftovi plus cetuximab to treat BRAFV600E-mutant mCRC

Pierre Fabre has secured EC approval for Braftovi plus cetuximab to treat BRAFV600E-mutant mCRC. (Credit: Jai79 from Pixabay)